Niravam Related Published Studies
Well-designed clinical trials related to Niravam (Alprazolam)
Does oral alprazolam affect ventilation? A randomised, double-blind, placebo-controlled trial. [2009.05]
Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet. [2007.08]
Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. [2007.05]
Current approaches to the pharmacologic treatment of anxiety disorders. [2007]
Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers. [2007]
Combining alprazolam with systematic desensitization therapy for dental injection phobia. [2007]
Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. [2006.11]
The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. [2006.10.01]
Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs. [2006.10]
Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers. [2006.09]
A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam. [2006.05]
[The cognitive effect of alprazolam in healthy volunteers] [2006]
A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. [2005.12]
Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. [2005.11]
A neurophysiological study of the detrimental effects of alprazolam on human action monitoring. [2005.10]
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. [2005.09]
Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer. [2005.08]
Effects of dehydroepiandrosterone and alprazolam on hypothalamic-pituitary responses to exercise. [2005.08]
A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam. [2005.06]
Sertraline and alprazolam in the treatment of panic desorder. [2005.05]
Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. [2005.05]
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. [2005.04]
A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. [2005.02.01]
Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers. [2005]
In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. [2004.10]
The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. [2004.10]
Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity. [2004.06]
Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers. [2004.06]
Interdose elevation in plasma cortisol during chronic treatment with alprazolam but not lorazepam in the elderly. [2004.03]
Influence of hydroxypropyl methylcellulose polymer on in vitro and in vivo performance of controlled release tablets containing alprazolam. [2003.11]
Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. [2003.08]
Well-designed clinical trials possibly related to Niravam (Alprazolam)
Benzodiazepines for delirium. [2009.10.07]
Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. [2009.07.24]
A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. [2009.03]
Benzodiazepines for delirium. [2009.01.21]
[Observation on the therapeutic effect of neck clustered needling on insomnia] [2008.12]
Clinical observation on post-stroke anxiety neurosis treated by acupuncture. [2008.09]
[Effect of acupuncture combined with massage of sole on sleeping quality of the patient with insomnia] [2008.06]
Relative influences of adjunctive topiramate and adjunctive lamotrigine on scanning and the effective field of view. [2008.02]
Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. [2007.09]
Effectiveness of a meditation-based stress management program as an adjunct to pharmacotherapy in patients with anxiety disorder. [2007.02]
Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications. [2007.02]
Clinical and electromyographic characteristics of tremor in patients with generalized anxiety disorder. [2007.01]
Connectivity analysis of EEG under drug therapy. [2007]
Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. [2006.11]
Modeling drug detection and diagnosis with the 'drug evaluation and classification program'. [2005.09]
Drug identification performance on the basis of observable signs and symptoms. [2005.09]
Effects of group experiential cognitive therapy for the treatment of panic disorder with agoraphobia. [2005.08]
Breast core-needle biopsy: clinical trial of relaxation technique versus medication versus no intervention for anxiety reduction. [2005.01]
[Evaluation of the usefulness and effectiveness of anxiolytic therapies in neoplastic diseases] [2004.06]
Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. [2004.02]
A 15-year follow-up study of patients with panic disorder. [2003.12]
Other research related to Niravam (Alprazolam)
Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine. [2009.07]
Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. [2009.07]
Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD. [2009.04]
Alprazolam intercalates into DNA. [2009.02]
Alprazolam and oxazepam block the cue-induced reinstatement of extinguished cocaine seeking in rats. [2009.01]
Does oral alprazolam affect ventilation? A randomised, double-blind, placebo-controlled trial. [2008.06.18]
Protective effect of alprazolam against sleep deprivation-induced behavior alterations and oxidative damage in mice. [2008.04]
An evaluation of data for 10 children born to mothers who attempted suicide by taking large doses of alprazolam during pregnancy. [2008.02]
Cognitive style, alprazolam plasma levels, and treatment response in panic disorder. [2008]
[Alprazolam use improves psychological status and reduces hospitalization costs in patients with paroxysmal supraventricular tachycardia underwent radiofrequency catheter ablation] [2007.10]
Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders. [2007.07.31]
Alprazolam induced conformational change in hemoglobin. [2007.06.01]
Protective effect of alprazolam in acute immobilization stress-induced certain behavioral and biochemical alterations in mice. [2007.05]
Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition. [2007.05]
Raman mapping of low-content API pharmaceutical formulations. I. Mapping of Alprazolam in Alprazolam/Xanax tablets. [2007.01]
Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. [2007]
Other possibly related research studies
Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model. [2008.07.17]
Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. [2008.05]
Evidenced-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics? [2008.02.25]
Efficacy of tropisetron in patients with advanced non-small-cell lung cancer receiving adjuvant chemotherapy with carboplatin and taxanes. [2008.03]
Effect of Jin-3-needling therapy on plasma corticosteroid, adrenocorticotrophic hormone and platelet 5-HT levels in patients with generalized anxiety disorder. [2007.12]
Opioid receptors are involved in the sedative and antinociceptive effects of hesperidin as well as in its potentiation with benzodiazepines. [2008.02.12]
Hemoperfusion in the treatment of acute clozapine intoxication in China. [2007.12]
[Therapeutical strategies for essential tremor] [2007.11.03]
An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. [2007.11]
Long-term, high-dose benzodiazepine prescriptions in veteran patients with PTSD: influence of preexisting alcoholism and drug-abuse diagnoses. [2007.10]
Pregabalin: Its efficacy, safety and tolerability profile in generalized anxiety. [2007.09]
Modulation of human risky decision making by flunitrazepam. [2008.02]
Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma. [2007.09]
Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. [2007.07]
Reversal of memory deficits by Atorvastatin and Simvastatin in rats. [2007.07]
Sustained inhibition of brotizolam induced anterograde amnesia by norharmane and retrograde amnesia by L-glutamic acid in mice. [2007.08.22]
Risk of acute liver injury associated with the use of drugs: a multicentre population survey. [2007.06.15]
Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. [2008.02]
Comparative effects of nonselective and subtype-selective gamma-aminobutyric acidA receptor positive modulators in the rat-conditioned emotional response test. [2007.05]
Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? [2007.04]
Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. [2007.08.15]
Anxiolytic-like effect of 5-HT(2) ligands and benzodiazepines co-administration: comparison of two animal models of anxiety (the four-plate test and the elevated plus maze). [2007.02.27]
[Gabapentin treatment in a female patient with panic disorder and adverse effects under carbamazepine during benzodiazepine withdrawal] [2007.03]
The treatment of depression in cancer patients: a systematic review. [2007.02]
Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4). [2007.04]
Clinical drugs that interact with St. John's wort and implication in drug development. [2008]
Tremor associated with chronic inflammatory demyelinating peripheral neuropathy: treatment with pregabalin. [2008.07]
GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety? [2008.07]
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. [2008.05]
Evidenced-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics? [2008.11]
Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function. [2008.04]
Using micro-attenuated total reflection spectroscopy to determine chemically induced changes in neat human hair: feasibility study on the effect of antipsychotic drugs. [2008.07]
A probable case of gabapentin-related reversible hearing loss in a patient with acute renal failure. [2008.09]
|
